Abraham Ceesay sold $324k of RAPP
Chief Executive Officer at Rapport Therapeutics, Inc.. 10,916 shares at an average of $29.64, traded Dec 17, 2025, filed Dec 18, 2025.
Score components
- +25RoleCEO
- +14Trade size$324k at market
- 0Share of holdings soldSold 1.9% of holdings
- +15Cluster3 insiders selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -9.5%, 3m -7.4%, 6m +26.0%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001193125-25-324826, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Dec 17, 2025 | SOpen-market sale Common Stock10b5-1 | -2,441 | $28.84 | $70k | 571,305 | Dec 18, 2025 |
| Dec 17, 2025 | SOpen-market sale Common Stock10b5-1 | -2,792 | $30.04 | $84k | 568,513 | Dec 18, 2025 |
| Dec 17, 2025 | SOpen-market sale Common Stock10b5-1 | -600 | $31.04 | $19k | 567,913 | Dec 18, 2025 |
| Dec 17, 2025 | SOpen-market sale Common Stockindirect: By Dorothy Ceesay Irrevocable Trust10b5-1 | -2,147 | $28.84 | $62k | 33,831 | Dec 18, 2025 |
| Dec 17, 2025 | SOpen-market sale Common Stockindirect: By Dorothy Ceesay Irrevocable Trust10b5-1 | -2,421 | $30.04 | $73k | 31,410 | Dec 18, 2025 |
| Dec 17, 2025 | SOpen-market sale Common Stockindirect: By Dorothy Ceesay Irrevocable Trust10b5-1 | -515 | $31.04 | $16k | 30,895 | Dec 18, 2025 |
Related signals
Other insiders at Rapport Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| Pro nowfree Oct 15, 2026 | Rapport Therapeutics, Inc. | Abraham Ceesay Chief Executive Officer | $143k 4,522 shares | -1% | |
| 23Weak | Rapport Therapeutics, Inc. | Cheryl Gault Chief Operating Officer | $332k 10,000 shares | -7% | |
| 22Weak | Rapport Therapeutics, Inc. | Abraham Ceesay Chief Executive Officer | $87k 2,210 shares | -0% | |
| 20Weak | Rapport Therapeutics, Inc. | Abraham Ceesay Chief Executive Officer | $374k 8,210 shares | -2% | |
| 37Weak | Rapport Therapeutics, Inc. | Abraham Ceesay Chief Executive Officer | $938k 18,921 shares | -4% | |
| 33Weak | Rapport Therapeutics, Inc. | Krishnaswamy Yeleswaram Chief Development Officer | $2.5M 50,160 shares | -20% | |
| 3Weak | Rapport Therapeutics, Inc. | Krishnaswamy Yeleswaram Chief Development Officer | $20k 404 shares | -0% | |
| 38Weak | Rapport Therapeutics, Inc. | Abraham Ceesay Chief Executive Officer | $2.4M 51,499 shares | -10% | |
| 15Weak | Rapport Therapeutics, Inc. | Abraham Ceesay Chief Executive Officer | $93k 2,210 shares | -0% | |
| 28Weak | Rapport Therapeutics, Inc. | Abraham Ceesay Chief Executive Officer | $328k 8,210 shares | -1% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.